Objectives: effects of konjac glucomannan (KGM) in adults with schizophrenia. Method post feasibility trial with 20 participants with elevated blood glucose, blood pressure, and triglycerides. Intervention konjac glucomannan for 1 to 1.5 h, 1 tablet times every day for 4 weeks, and were encouraged to practise the exercises at home. Main Outcome Measures Indicators of blood pressure, fasting blood glucose, triglycerides, and schizophrenia symptoms. Results: There was high acceptability and good adherence. There were significant improvements in four indicators of metabolic syndrome including; Cholesterol (p,0.037), systolic (p,0.037) and diastolic blood pressure (p,0.869), as well as in GDP (p,0.004), schizophrenia symptoms (p,0.000). Conclusions: The program was feasible and acceptable, and participants' physiologic and physiological variables continued to improve. A larger controlled trial is now required to confirm these encouraging preliminary findings.